Nilotinib Benefits Relapsed Patients With CML After Treatment Discontinuation
June 18th 2019Jorge E. Cortes, MD, discusses the results from the ENESTFreedom study, which evaluated the use of nilotinib as a treatment for patients with BCR-ABL1–positive chronic myeloid leukemia in the chronic phase.<br />